KRAS and colorectal carcinoma: Lan et al. reported that the proportion of PM was significantly higher in stage I–IV CRC patients whose tumors carried a RAS pathway mutation, and KRAS-mutated tumors had a trend toward a higher proportion of PM, which was not significant [28].